{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:56:17Z","timestamp":1792252577254,"version":"4.4.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>A single-center retrospective study was conducted according to the latest diagnostic criteria of the European Consortium for Mycology in Medicine\/International Society for Human and Animal Mycoses (ECMM\/ISHAM) Consensus, which describes the clinical characteristics, factors influencing and prognosis of a group of patients with COVID-19 (Omicron variant) combined with invasive pulmonary mycoses with onset of disease at the end of 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study retrospectively analyzed data related to 58 hospitalized patients with severe pneumonia due to COVID-19 infection admitted to the ICU of critical care medicine, respiratory ICU, and ICU of the Department of Infections at the First Affiliated Hospital of Soochow University from December 1, 2022, to January 31, 2023. CAPA was defined according to the ECMM\/ISHAM consensus criteria. Our study compared the clinical and microbiological characteristics and associated risk factors of fungal infections and pulmonary fungal infections and performed univariate and multivariate analyses of factors associated with mortality in patients with COVID-19-Associated Pulmonary Aspergillosis (CAPA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>17 (29.3%) of the 58 critically ill patients were diagnosed with CAPA, of which 10 (58.82%) patients were Probable CAPA and 7 (41.18%) patients were Possible CAPA. Among this <jats:italic>Aspergillus<\/jats:italic> strains, <jats:italic>Aspergillus fumigatus<\/jats:italic> strains were found in 13 cases (76.47%) and <jats:italic>Aspergillus niger<\/jats:italic> strains in 4 cases (23.53%). 7 (41.18%) patients had concomitant bacterial fungal infections with a mortality rate of 57.14% (4\/7), of which <jats:italic>Acinetobacter baumannii<\/jats:italic> was the most common pathogen. Among the patients with CAPA, galactomannan assay of bronchoalveolar lavage fluid (BALF) was performed in 5 patients with a 100% (5\/5) positivity rate, and two or more serum galactomannan (GM) assays were performed in 17 patients, with a probability of favorable results in both cases of 41.2% (7\/17). The 60-day mortality rate in patients with CAPA was 52.9% (9\/17), whereas the non-CAPA patients had a 60-day mortality rate of 24.4% (10\/41), which was statistically different (P = 0.035). Diabetes mellitus (P = 0.018, OR: 5.040 (95% CI: 1.314-19.337)), renal insufficiency (P=0.002, OR: 11.259 (95% CI: 2.480-51.111)), chronic obstructive pulmonary disease (COPD) (P = 0.003, OR: 6.939 (95% CI: 1.963-24.531)), elevated interleukin-6 (IL-6) (P = 0.022, OR: 4.160 (95% CI: 1.226~14.113)), mechanical ventilation (P = 0.002, OR: 8.100 (95%CI: 2.132~30.777)), increased duration of steroids use (P = 0.022, OR: 1.071 (95%CI: 1.010~1.135)), increased cumulative dose of steroids use ((P &amp;lt; 0.001, OR: 1.012 (95%CI: 1.009~1.015)), use of tocilizumab (P = 0.020, OR: 11.480 (95%CI: 2.480~51.111)), and increased length of hospitalization in ICU (P = 0.021, OR: 1.038 (95% CI: 1.006 to 1.071)), and increase in the type of antibiotics used (P = 0.002, OR: 1.603 (95% CI: 1.181 to 2.176)) were the risk factors for the occurrence of fungal infections, whereas the use of steroids or not, the use of baricitinib or not, and hypertension did not have a significant effect on the occurrence of fungal infections (P &amp;gt; 0.05). Patients with CAPA had a higher mortality rate, and their hospitalization was prolonged compared to non-CAPA patients. The all-cause mortality rate for patients with CAPA was 52.9%. We also performed univariate and multivariate analyses of potential factors associated with mortality, including the use of mechanical ventilation (P = 0.040 OR: 10.500, (95% CI: 1.115 to 98.914)), advanced age (P = 0.043 OR: 1.212, (95% CI: 1.006 to 1.460)), and a significantly higher CRP level (P = 0.042 OR: 1.043, (95% CI: 1.002~1.078)) had a worse prognosis. Steroids use, gender, and diabetes mellitus were not associated with patient death (P &amp;gt; 0.05).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2025.1522217","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:27:44Z","timestamp":1745299664000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical characteristics and prognosis of COVID-19- associated invasive pulmonary aspergillosis in critically patients: a single-center study"],"prefix":"10.3389","volume":"15","author":[{"given":"Shuang","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cmi.2022.07.008","article-title":"Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis","volume":"29","author":"Albuquerque","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2002554","DOI":"10.1183\/13993003.02554-2020","article-title":"Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis","volume":"56","author":"Armstrong-James","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13020150","article-title":"The prognostic role of diagnostic criteria for COVID-19-associated pulmonary aspergillosis: A cross-sectional retrospective study","volume":"13","author":"Asperges","year":"2024","journal-title":"Antibiotics."},{"key":"B4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10096-020-04142-w","article-title":"Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome","volume":"40","author":"Bardi","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5144\/0256-4947.2023.243","article-title":"Prevalence of secondary infections and association with mortality rates of hospitalized COVID-19 patients","volume":"43","author":"Binkhamis","year":"2023","journal-title":"Ann. Saudi. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/1751-7915.14064","article-title":"COVID-19: Omicron - the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2","volume":"15","author":"Br\u00fcssow","year":"2022","journal-title":"Microb. Biotechnol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.idc.2021.03.008","article-title":"Aspergillosis: epidemiology, diagnosis, and treatment","volume":"35","author":"Cadena","year":"2021","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"B8","first-page":"71","article-title":"Invasive fungal infections in patients with COVID-19: A review onpatho-genesis, epidemiology, clinical features, treatment, and outcomes","volume":"44","author":"Chiurlo","year":"2021","journal-title":"New. Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s15010-021-01701-x","article-title":"Comparing the clinical characteristics and out-comes of COVID-19-associate pulmonary aspergillosis (CAPA): a systematic review and meta-analysis","volume":"50","author":"Chong","year":"2022","journal-title":"Infection."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10111370","article-title":"Incidence and risk factors of COVID-19-associated pulmonary aspergillosis in intensive care unit-A monocentric retrospective observational study","volume":"10","author":"Gregoire","year":"2021","journal-title":"Pathogens."},{"key":"B11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/myc.13637","article-title":"Effect of glucocorticoids on the development of COVID-19-associated pulmonary aspergillosis: A meta-analysis of 21 studies and 5174 patients","volume":"66","author":"Hashim","year":"2023","journal-title":"Mycoses."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13693","article-title":"Clinical characteristics, bacterial coinfections and outcomes in COVID-19-associated pulmonary aspergillosis in a third-level Mexican hospital during the COVID-19 pre-vaccination era","volume":"67","author":"Hern\u00e1ndez-Silva","year":"2024","journal-title":"Mycoses."},{"key":"B13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.cmi.2022.01.027","article-title":"Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis","volume":"28","author":"Kariyawasam","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/infdis\/jiab163","article-title":"Navigating the uncertainties of COVID-19-associated aspergillosis: A comparison with influenza-associated aspergillosis","volume":"224","author":"Lamoth","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/myc.13292","article-title":"Incidence and mortality of COVID-19-associated pulmonary aspergillosis: A systematic review and meta-analysis","volume":"64","author":"Mitaka","year":"2021","journal-title":"Mycoses."},{"key":"B16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.12688\/f1000research.74566.2","article-title":"Bacterial and fungal co-infections among ICU COVID-19 hospitalized patients in a Palestinian hospital: a retrospective cross-sectional study","volume":"11","author":"Naseef","year":"2022","journal-title":"F1000Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/myc.13341","article-title":"A review of significance of Aspergillus detection in airways of ICU COVID-19 patients","volume":"64","author":"Pasquier","year":"2021","journal-title":"Mycoses."},{"key":"B18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.cmi.2021.08.014","article-title":"Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology","volume":"28","author":"Prattes","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2022.127204","article-title":"Omicron variant: Current insights and future directions","volume":"265","author":"Rana","year":"2022","journal-title":"Microbiol. Res."},{"key":"B20","unstructured":"Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19\n          \n          2020"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24298","article-title":"COVID-19-associated pulmonary aspergillosis in intensive care unit: A real-life experience","volume":"10","author":"Russo","year":"2024","journal-title":"Heliyon."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101489","article-title":"Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials","volume":"49","author":"Selvaraj","year":"2022","journal-title":"EClinicalMedicine."},{"key":"B23","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1183\/13993003.01282-2015","article-title":"Influenza virus damages the alveolar barrier by disrupting epithelial cell tight junctions","volume":"47","author":"Short","year":"2016","journal-title":"Eur. Respir. J."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/jof9060666","article-title":"COVID-19-associated pulmonary aspergillosis in intensive care unit patients from Poland","volume":"9","author":"Sk\u00f3ra","year":"2023","journal-title":"J. Fungi."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa242","article-title":"Invasive aspergillosis as an under-recognized superinfection in COVID-19. Open","volume":"7","author":"Thompson Iii","year":"2020","journal-title":"Forum. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2023.154272","article-title":"Incidence, risk factors and pre-emptive screening for COVID-19 associated pulmonary aspergillosis in an era of immunomodulant therapy","volume":"76","author":"van Grootveld","year":"2023","journal-title":"J. Crit. Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00134-021-06449-4","article-title":"Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis","volume":"47","author":"Verweij","year":"2021","journal-title":"Intensive Care Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jmii.2022.09.006","article-title":"Coronavirus disease 2019 (COVID-19) associated bacterial coinfection: Incidence, diagnosis and treatment","volume":"55","author":"Wu","year":"2022","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.733","article-title":"Emergence of SARS-CoV-2 Omicron variant and strategies for tackling the infection","volume":"10","author":"Wu","year":"2022","journal-title":"Immun. Inflamm. Dis."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1522217\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:27:47Z","timestamp":1745299667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1522217\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":29,"alternative-id":["10.3389\/fcimb.2025.1522217"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1522217","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"article-number":"1522217"}}